Rurioctocog alfa pegol
- Generic Name
- Rurioctocog alfa pegol
- Brand Names
- Adynovi
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 1417412-83-9
- Unique Ingredient Identifier
- -
- Background
Rurioctocog alfa pegol is a pegylated recombinant human coagulation factor VIII or antihemophilic factor. Factor VIII is an essential protein involved in normal blood clotting; thus, a deficient level of functional factor VIII is associated with an elevated risk for excessive bleeding caused by spontaneous or secondary events like trauma or surgery. Hemophil...
- Indication
Rurioctocog alfa pegol is indicated for the treatment and prophylaxis of bleeding in patients 12 years and above with hemophilia A (congenital factor VIII deficiency).
- Associated Conditions
- Bleeding caused by Hemophilia A
- Associated Therapies
- -
Pharmacokinetic Assessment of Standard Half-Life (SHL) FVIII, Extended Half-Life (EHL) FVIII, and Efanesoctocog Alfa (BIVV001) in Severe Hemophilia A
- Conditions
- Interventions
- First Posted Date
- 2021-09-13
- Last Posted Date
- 2023-08-03
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 13
- Registration Number
- NCT05042440
- Locations
- 🇧🇬
Investigational Site Number :1000001, Sofia, Bulgaria
Pharmacokinetic Characterization of the Hemophilia A Population in Spain Using myPKFiT®
- Conditions
- Interventions
- First Posted Date
- 2016-12-30
- Last Posted Date
- 2023-06-08
- Lead Sponsor
- Spanish Society of Thrombosis and Haemostasis
- Target Recruit Count
- 50
- Registration Number
- NCT03006965
- Locations
- 🇪🇸
Hospital Universitario Virgen de la Arrixaca, El Palmar, Murcia, Spain
🇪🇸Hospital Virgen del Camino, Pamplona, Navarra, Spain
🇪🇸Hospital Xeral de Vigo, Vigo, Pontevedra, Spain
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.